Find out everything you need to know about pembrolizumab in urothelial carcinoma in our video tutorial!
In our Medudy course, we show you the latest findings on the treatment of muscle-invasive urothelial carcinoma, including the current data on the use of pembrolizumab. This tutorial has been specially developed for physicians and summarizes current and important studies in a compact "Journal Club Summary".
Muscle-invasive urothelial carcinoma: What you should know
Muscle-invasive urothelial carcinoma is an aggressive disease with a high recurrence rate. The standard for cisplatin-eligible patients is neoadjuvant chemotherapy. However, many patients are not suitable for cisplatin or continue to have muscle-invasive disease despite chemotherapy and surgery. Pembrolizumab plays an important role in adjuvant therapy for urothelial carcinoma.
This is where pembrolizumab comes into play: it is being investigated as an adjuvant therapy for high-risk patients after surgery. We will show you whether this treatment could be useful and the results of the latest studies. Information on the role of pembrolizumab in urothelial carcinoma is presented in detail.
This is what you will learn in this course:
At the end of the course you will be able to:
- understand why the research question is important,
- understand the study design and methodology,
- evaluate the study results,
- classify possible advantages and limitations of the therapy, in particular pembrolizumab in urothelial carcinoma.
Easy to understand thanks to AI avatars
Our videos are presented by AI avatars based on real people. All content comes from high-quality scientific sources and is carefully reviewed by our Medudy medical team. This approach makes the use of pembrolizumab in urothelial carcinoma easy to understand.
Register now and deepen your knowledge!
